Cofepris
- All
- News
-
Mexico Grants Authorisation For Emergency Use Of India's Covaxin Vaccine
The Mexico Federal Commission for the Protection Against Sanitary Risk (Cofepris) on Wednesday has granted authorization for the emergency use of India's first domestically-produced COVID-19 vaccine, Covaxin.
-
World's First Anti-Dengue Vaccine Brings Hope For India
At a time when India is struggling with rising number of dengue cases with each passing year, the Mexican government has approved the world's first anti-dengue vaccine which is designed to protect people in the 9-45 age group from nine to 45 years from all four subtypes of the virus.
-
Biocon Jumps on Approval for Insulin in Mexico
Company's insulin Glargine has been approved by Cofepris, the Mexican health authority, through its Mexican partner PiSA Farmaceutica (PiSA), Biocon said in a statement.
-
Biocon gets Approval for Insulin Glargine in Mexico
The company's insulin Glargine has been approved by Cofepris, the Mexican health authority, through its Mexican partner PiSA Farmaceutica (PiSA), Biocon said in a statement.
-
Mexico Grants Authorisation For Emergency Use Of India's Covaxin Vaccine
The Mexico Federal Commission for the Protection Against Sanitary Risk (Cofepris) on Wednesday has granted authorization for the emergency use of India's first domestically-produced COVID-19 vaccine, Covaxin.
-
World's First Anti-Dengue Vaccine Brings Hope For India
At a time when India is struggling with rising number of dengue cases with each passing year, the Mexican government has approved the world's first anti-dengue vaccine which is designed to protect people in the 9-45 age group from nine to 45 years from all four subtypes of the virus.
-
Biocon Jumps on Approval for Insulin in Mexico
Company's insulin Glargine has been approved by Cofepris, the Mexican health authority, through its Mexican partner PiSA Farmaceutica (PiSA), Biocon said in a statement.
-
Biocon gets Approval for Insulin Glargine in Mexico
The company's insulin Glargine has been approved by Cofepris, the Mexican health authority, through its Mexican partner PiSA Farmaceutica (PiSA), Biocon said in a statement.
